ArticlePloS one2026
Machine learning-inspired similarity measure to forecast M&A from patent data.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Defining and finalizing Mergers and Acquisitions (M&A) requires complex human skills, which makes it very hard to automatically find the best partner or predict which firms will make a deal. In this work, we propose the MASS algorithm, which adapts a patent-based measure of similarity between companies to forecast M&A deals. MASS is based on an extreme simplification of tree-based machine learning algorithms and naturally incorporates intuitive criteria for deals; as such, it is fully interpretable and explainable. By applying MASS to the Zephyr and Crunchbase datasets, we show that it outperforms a more "black box" graph convolutional network algorithm. The latter, however, turns out to be the most effective algorithm when considering companies with disjoint patenting activities. This study provides a simple and powerful tool to model and predict M&A deals between companies active in patenting, offering valuable insights to managers and practitioners for informed decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.